Originally an antiviral drug-candidate, ABX464 has successfully
expanded into development as an anti-inflammatory candidate
Key opinion leader, Prof. Ian McGowan and Abivax management to
present and answer questions
ABX464 recently showed statistically significant clinical and
endoscopic benefit in a Phase 2a trial in ulcerative colitis (UC)
patients
PARIS--(BUSINESS WIRE)--Nov. 9, 2018--
Regulatory News:
Abivax (Paris:ABVX) (Euronext Paris: FR0012333284 – ABVX), a
clinical-stage biopharmaceutical company harnessing the immune system to
develop novel treatments for patients with inflammatory/autoimmune
diseases, viral infections and cancer, today announced it will host a
key opinion leader event on a potential novel first-in-class approach to
treating inflammatory diseases.
Details of the event are as follows:
Time: Today (Friday, November 9, 2018)
- 12:15 pm CET - Registration
- 12:30-2:00 pm CET - Presentations
Webcast Information:
For those who are unable to attend in person, a live webcast and replay
will be accessible via the link http://abivax.streameo.info/live.html
Q&A Information:
If you would like to ask a question during the live Q&A, you can submit
your request electronically during the webcast.
The meeting will focus on ABX464, an antiviral drug that is expanding to
become a broad anti-inflammatory. It will feature a presentation by key
opinion leader Prof. Ian McGowan, MD, PhD, from the University of
Pittsburgh School of Medicine, and the Abivax management team, who will
describe the scientific data that led Abivax to put ABX464, already a
successful clinical drug-candidate for HIV treatment, into the recently
announced successful Phase 2a trial for ulcerative colitis (UC).
“We are very much looking forward to hosting this event with Dr.
McGowan, who is a widely respected authority in the field of HIV/AIDS,
and who will give us the benefit of his expertise on the potential of
ABX464,” said Pr. Hartmut J Ehrlich, CEO of Abivax.“ABX464
has already been shown to had already been shown to be the first
treatment to reduce HIV reservoir in the blood and gut tissue of
well-controlled HIV patients. It also has an impressive
anti-inflammatory effect that has broad potential for treatment of UC,
Crohn’s disease, rheumatoid arthritis, multiple sclerosis and other
inflammatory diseases.”
Dr. McGowan is a Professor of Medicine in the Division of
Gastroenterology, Hepatology and Nutrition at the University of
Pittsburgh School of Medicine. He is a gastroenterologist and
distinguished expert in the field. He qualified in medicine at the
University of Liverpool, Liverpool, UK and has doctoral degrees from the
University of Oxford (Mucosal Immunity) and the Liverpool School of
Tropical Medicine (Microbicide Development). For the last decade, Dr.
McGowan has been the Principal Investigator of the University of
Pittsburgh-based Microbicide Trials Network (MTN), an HIV/AIDS clinical
trials network established in 2006 by the National Institute of Allergy
and Infectious Diseases, part of the U.S. National Institutes of Health
(NIH). Dr. McGowan has also served as a consultant for the U.S. Centers
for Disease Control and Prevention, the World Health Organization, and
is a former Chair of the U.S. Food and Drug Administration Antiviral
Drug Advisory Committee.
ABX464, an oral once-daily small molecule modulator of RNA biogenesis,
statistically significantly improved both clinical and endoscopic
endpoints in the placebo-controlled European trial in 32 UC patients.
The presentations and discussion will be in English. Dr. McGowan will be
available to answer questions following the lunch. Abivax's management
team also will provide an overview of recent Phase 2a UC data and the
Company’s plans for ABX464 and will also be available to answer
questions. Questions also can be submitted electronically via the
webcast.
About ABIVAX (www.abivax.com)
ABIVAX is mobilizing the body’s natural immune machinery to treat
patients with viral infections, autoimmune diseases and cancer. A
clinical-stage company, ABIVAX leverages its antiviral and immune
enhancing platforms to optimize candidates to cure HIV and treat
inflammatory bowel diseases, as well as liver cancer. ABIVAX is listed
on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). More
information on the company is available at www.abivax.com/en.
Follow us on Twitter @ABIVAX_
View source version on businesswire.com: https://www.businesswire.com/news/home/20181108005774/en/
Source: Abivax
Abivax
Finance
Didier Blondel, +33 1 53 83 08 41
didier.blondel@abivax.com
or
Investors
LifeSci
Advisors
Chris Maggos, +41 79 367 6254
chris@lifesciadvisors.com
or
French
Media
ALIZE RP
Caroline Carmagnol/Margaux Pronost,
+33 6 64 18 99 59 / +33 1 44 54 36 65
abivax@alizerp.com
or
US
Media
LifeSci Public Relations
Matt Middleman,
M.D., +1-646-627-8384
matt@lifescipublicrelations.com
or
Press
Relations and Investors Europe
MC Services AG
Anne
Hennecke, +49 211 529 252 22
anne.hennecke@mc-services.eu
